Skip Navigation


Chemoprevention for Barrett's Esophagus Trial (CBET)

CBET is a randomized, multicenter, masked, placebo-controlled study of the cyclooxygenase-2 (COX-2) inhibitor celecoxib. One hundred participants with high- or low-grade Barrett's dysplasia were randomized to placebo or celecoxib. Study medication (celecoxib or placebo) was administered orally, 200 mg twice per day.

Randomization was stratified by dysplasia grade and by clinic. Eligible individuals are 18 years of age or older and have an established diagnosis of Barrett's dysplasia with specific information on the location of the highest grade of dysplasia from a biopsy.



© , Johns Hopkins University. All rights reserved.
Web policies, 615 N. Wolfe Street, Baltimore, MD 21205